Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: A follow-up study of 148 patients

International Journal of Cancer

Volumn 121, Issue 3, 2007, Pages 689-693

  Starz, Hans ^a   Balda, Bernd Ruediger ^a  

^a KLINIKUM AUGSBURG   (Germany)

Author keywords

Follow up; Melanoma; Metastasis; S classification; Sentinel lymph node; Skin; Survival; Tumor thickness

Indexed keywords

ADULT; ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34250876810     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22707     Document Type: Article

References (28)

1. Cochran AJ, Balda BR, Starz H, Bachter D, Krag DN, Cruse CW, Pijpers R, Morton DL. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer 2000;89:236-41.
2. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976-83.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
4. Starz H, Balda BR, Krämer KU, Büchels H, Wang HJ. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer 2001;91:2110-21.
5. Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol 2001;44:762-6.
6. Starz H, De Donno A, Balda BR. The Augsburg experience: histological aspects and patient outcomes. Ann Surg Oncol 2001;8(9 Suppl): 48S-51S.
7. Starz H, Siedlecki K, Balda BR. Sentinel lymphonodectomy and S-classification: a successful strategy for better prediction and improvement of outcome of melanoma. Ann Surg Oncol (United States) 2004;11(3 Suppl):162S-8S.
8. Morton DL, Hoon DS, Cochran AJ, Turner RR, Essner R, Takeuchi H, Wanek LA, Glass E, Foshag LJ, Hsueh EC, Bilchik AJ, Elashoff D, et al. Lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: therapeutic utility and implications of nodal microanatomy and molecular staging for improving the accuracy of detection of nodal micrometastases. Ann Surg 2003;238:538-49.
9. Kretschmer L, Hilgers R, Möhrle M, Balda B-R, Breuninger H, Konz B, Kunte C, Marsch WC, Neumann C, Starz H. Patients with lymphatic metastasis of cutaneous malignant melanoma benefit from sentinel lymphonodectomy and early excision of their nodal disease. Eur J Cancer 2004;40:212-8.
10. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005; 153:1137-41.
11. Volkenandt M, Schmidt M, Konz B, Gummer M, Hein R, Plewig G, Hölzel D. Clinical and epidemiological data of patients with malignant melanoma from the Munich Tumor Center 1977-1997. Hautarzt 1999;50:470-8.
12. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-41.
13. Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann R-D, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, et al. Kurzleitlinie: Malignes Melanom der Haut JDDG 2006;4:344-9.
14. Corsetti RL, Allen HM, Wanebo HJ. Thin ≤1 mm level III and IV melanomas are higher risk lesions for regional failure and warrant sentinel lymph node biopsy. Ann Surg Oncol 2000;7:456-60.
15. Breslow A. Tumor thickness in evaluating prognosis of cutaneous melanoma. Ann Surg 1978;187:440.
16. Starz H, Balda B-R. Sentinel lymphonodectomy and micromorphometric S-staging, a successful new strategy in the management of cutaneous malignancies. Giorn Ital Dermatol Venereol 2000;135:161-9.
17. Bedrosian I, Faries MB, Guerry D, Elenitsas R, Schuchter L, Mick R, Spitz FR, Bucky LP, Alavi A, Elder DE, Fraker DL, Czerniecki BJ. Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-7.
18. Puleo CA, Messina JL, Riker AI, Glass LF, Nelson C, Cruse CW, Johnson TM, Sondak VK. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005;12:230-5.
19. Bachter D, Starz H, Volkmar Ch, Vogt H, Büchels H, Balda B-R. The sentinel-lymphonodectomy in malignant melanoma. Der Nuklearmediziner 1999;4:245-52.
20. Starz H, Cochran AJ, Balda B-R. Histopathological aspects of the sentinel lymphonodectomy. Akt Dermatol 2002;28:273-8.
21. Starz H. Pathology of the sentinel lymph node in melanoma. Semin Oncol 2004;31:357-62.
22. Balda B-R, Starz H. Histological aspects of sentinel lymphonodectomy in dermato-oncology with special regard to malignant melanoma. In: Tomasini C, Pippione M, eds. Dermatopathology collection. Torino: Medical Communications, 2006; 155-62.
23. Clemente CG, Mihm MC, Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77: 1303-10.
24. Balda B-R, Starz H. Malignant melanoma. In: Katsambas AD, Lotti TM, eds. European Handbook of Dermatological Treatments,2nd edn. Berlin: Springer, 2003; 321-9.
25. Bleicher RJ, Essner R, Forshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:1326-31.
26. Thomas JM. Time to re-evaluate sentinel node biopsy in melanoma post-multicenter selective lymphadenectomy trial. J Clin Oncol 2005; 23:9443-4.
27. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Rec Res Cancer Res 2000;157:55-81.
28. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness ≤1.0 mm). Ann Surg Oncol 2004;11:900-6.